Engineered drug-loaded cellular membrane nanovesicles for efficient treatment of postsurgical cancer recurrence and metastasis
Cancer recurrence and metastasis are still common causes of postsurgery death in patients with solid tumors, suggesting that additional consolidation therapeutic strategies are necessary. We have previously found that oxaliplatin (OXA) treatment causes further up-regulation of CD155, which is abunda...
| Main Authors: | , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Journal Article |
| Language: | English |
| Published: |
2023
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/10356/168694 |
| _version_ | 1811680848231006208 |
|---|---|
| author | Yu, Yongkang Cheng, Qinzhen Ji, Xiaoyuan Chen, Hongzhong Zeng, Wenfeng Zeng, Xiaowei Zhao, Yanli Mei, Lin |
| author2 | School of Chemistry, Chemical Engineering and Biotechnology |
| author_facet | School of Chemistry, Chemical Engineering and Biotechnology Yu, Yongkang Cheng, Qinzhen Ji, Xiaoyuan Chen, Hongzhong Zeng, Wenfeng Zeng, Xiaowei Zhao, Yanli Mei, Lin |
| author_sort | Yu, Yongkang |
| collection | NTU |
| description | Cancer recurrence and metastasis are still common causes of postsurgery death in patients with solid tumors, suggesting that additional consolidation therapeutic strategies are necessary. We have previously found that oxaliplatin (OXA) treatment causes further up-regulation of CD155, which is abundantly expressed in tumors for resulting in increased sensitivity of cancer to anti-CD155 therapy. Here, we report O-TPNVs, which are TIGIT-expressing cell membrane and platelet cell membrane fusion nanovesicles (TPNVs) loaded with OXA. Platelet-derived membrane components enable O-TPNVs to target postsurgery wounds and interact with circulating tumor cells (CTCs). OXA directly kills residual tumor cells and CTCs, induces immunogenic cell death, and activates the immune system. TPNVs bind to CD155 on tumor cells, block the CD155/TIGIT pathway, and restore CD8+ T cell activity. In vivo analyses reveal that O-TPNVs achieve synergistic chemotherapeutic and immunotherapeutic effects, effectively inhibiting the recurrence and metastasis of triple-negative breast cancer (4T1) after surgery. |
| first_indexed | 2024-10-01T03:31:34Z |
| format | Journal Article |
| id | ntu-10356/168694 |
| institution | Nanyang Technological University |
| language | English |
| last_indexed | 2024-10-01T03:31:34Z |
| publishDate | 2023 |
| record_format | dspace |
| spelling | ntu-10356/1686942023-06-16T15:31:42Z Engineered drug-loaded cellular membrane nanovesicles for efficient treatment of postsurgical cancer recurrence and metastasis Yu, Yongkang Cheng, Qinzhen Ji, Xiaoyuan Chen, Hongzhong Zeng, Wenfeng Zeng, Xiaowei Zhao, Yanli Mei, Lin School of Chemistry, Chemical Engineering and Biotechnology Science::Chemistry Cancer Recurrence Cellular Membranes Cancer recurrence and metastasis are still common causes of postsurgery death in patients with solid tumors, suggesting that additional consolidation therapeutic strategies are necessary. We have previously found that oxaliplatin (OXA) treatment causes further up-regulation of CD155, which is abundantly expressed in tumors for resulting in increased sensitivity of cancer to anti-CD155 therapy. Here, we report O-TPNVs, which are TIGIT-expressing cell membrane and platelet cell membrane fusion nanovesicles (TPNVs) loaded with OXA. Platelet-derived membrane components enable O-TPNVs to target postsurgery wounds and interact with circulating tumor cells (CTCs). OXA directly kills residual tumor cells and CTCs, induces immunogenic cell death, and activates the immune system. TPNVs bind to CD155 on tumor cells, block the CD155/TIGIT pathway, and restore CD8+ T cell activity. In vivo analyses reveal that O-TPNVs achieve synergistic chemotherapeutic and immunotherapeutic effects, effectively inhibiting the recurrence and metastasis of triple-negative breast cancer (4T1) after surgery. National Research Foundation (NRF) Published version This work was supported by the National Natural Science Foundation of China (31922042 and 82272154), the Shenzhen Science and Technology Program (GXWD20201231165807008 and 20200825175848001), the Fundamental Research Funds for the Central Universities (2021-RC310-005 and 2020-RC320-002), the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (2021-I2M-1-058), and the Singapore National Research Foundation under its Competitive Research Programme (NRF-CRP26-2021-0002). 2023-06-15T04:21:35Z 2023-06-15T04:21:35Z 2022 Journal Article Yu, Y., Cheng, Q., Ji, X., Chen, H., Zeng, W., Zeng, X., Zhao, Y. & Mei, L. (2022). Engineered drug-loaded cellular membrane nanovesicles for efficient treatment of postsurgical cancer recurrence and metastasis. Science Advances, 8(49), eadd3599-. https://dx.doi.org/10.1126/sciadv.add3599 2375-2548 https://hdl.handle.net/10356/168694 10.1126/sciadv.add3599 36490349 2-s2.0-85143917276 49 8 eadd3599 en NRF-CRP26-2021-0002 Science Advances © 2022 The Authors,some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC). application/pdf |
| spellingShingle | Science::Chemistry Cancer Recurrence Cellular Membranes Yu, Yongkang Cheng, Qinzhen Ji, Xiaoyuan Chen, Hongzhong Zeng, Wenfeng Zeng, Xiaowei Zhao, Yanli Mei, Lin Engineered drug-loaded cellular membrane nanovesicles for efficient treatment of postsurgical cancer recurrence and metastasis |
| title | Engineered drug-loaded cellular membrane nanovesicles for efficient treatment of postsurgical cancer recurrence and metastasis |
| title_full | Engineered drug-loaded cellular membrane nanovesicles for efficient treatment of postsurgical cancer recurrence and metastasis |
| title_fullStr | Engineered drug-loaded cellular membrane nanovesicles for efficient treatment of postsurgical cancer recurrence and metastasis |
| title_full_unstemmed | Engineered drug-loaded cellular membrane nanovesicles for efficient treatment of postsurgical cancer recurrence and metastasis |
| title_short | Engineered drug-loaded cellular membrane nanovesicles for efficient treatment of postsurgical cancer recurrence and metastasis |
| title_sort | engineered drug loaded cellular membrane nanovesicles for efficient treatment of postsurgical cancer recurrence and metastasis |
| topic | Science::Chemistry Cancer Recurrence Cellular Membranes |
| url | https://hdl.handle.net/10356/168694 |
| work_keys_str_mv | AT yuyongkang engineereddrugloadedcellularmembranenanovesiclesforefficienttreatmentofpostsurgicalcancerrecurrenceandmetastasis AT chengqinzhen engineereddrugloadedcellularmembranenanovesiclesforefficienttreatmentofpostsurgicalcancerrecurrenceandmetastasis AT jixiaoyuan engineereddrugloadedcellularmembranenanovesiclesforefficienttreatmentofpostsurgicalcancerrecurrenceandmetastasis AT chenhongzhong engineereddrugloadedcellularmembranenanovesiclesforefficienttreatmentofpostsurgicalcancerrecurrenceandmetastasis AT zengwenfeng engineereddrugloadedcellularmembranenanovesiclesforefficienttreatmentofpostsurgicalcancerrecurrenceandmetastasis AT zengxiaowei engineereddrugloadedcellularmembranenanovesiclesforefficienttreatmentofpostsurgicalcancerrecurrenceandmetastasis AT zhaoyanli engineereddrugloadedcellularmembranenanovesiclesforefficienttreatmentofpostsurgicalcancerrecurrenceandmetastasis AT meilin engineereddrugloadedcellularmembranenanovesiclesforefficienttreatmentofpostsurgicalcancerrecurrenceandmetastasis |